Previous 10 | Next 10 |
Panbela Therapeutics ( NASDAQ: PBLA ) prices a public offering of (i) 20.1M shares of stock, warrants to purchase up to 30.15M shares at a purchase price of $0.30. Warrants will have an exercise price of $0.30 per share, are exercisable upon issuance, and will expire five ...
MINNEAPOLIS, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), (“Panbela” or the “Company”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announce...
MINNEAPOLIS, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced Regulatory approval for the opening of trial sites in Sp...
Panbela Therapeutics, Inc. (PBLA) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Jennifer Simpson – Chief Executive Officer Sue Horvath – Chief Financial Officer Conference Call Participants Tony Butler ...
Panbela Therapeutics press release ( NASDAQ: PBLA ): Q2 GAAP EPS of -$1.51. Total cash was $2.5M as of June 30, 2022. For further details see: Panbela Therapeutics GAAP EPS of -$1.51
MINNEAPOLIS, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA) , a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the qu...
MINNEAPOLIS, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced it has enrolled the first patient in its global clinical ...
MINNEAPOLIS, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced it has received approval from the Australian Human Resear...
MINNEAPOLIS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA) , a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on August 15, 2022, a...
Gainers: Seritage Growth Properties ( SRG ) +72% . Aditxt ( ADTX ) +70% . Humanigen ( HGEN ) +35% . Clovis Oncology ( CLVS ) +30% . MyMD Pharmaceuticals ( MYMD ) +27% . Oramed Pharmaceuticals ( ORMP ) +26% . Kura ...
News, Short Squeeze, Breakout and More Instantly...
Panbela Therapeutics Inc Com Company Name:
PBLA Stock Symbol:
NASDAQ Market:
Panbela Therapeutics Inc Com Website:
DSMB Recommends Continuation without Modification for Third Time Safety Review Included 395 Patients Interim Survival Analysis Still Expected Early 2025 given Lower-Than-Expected Event Rate Low Event Rate Suggests Potential for Prolonged Survival Rapid Enrollment P...
MINNEAPOLIS, June 10, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announces an oral presentation at the Digestive Disease Week (DDW) conference,...
MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the q...